Metastatic Pancreatic CancerPhase 1NCT06532344
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
A Phase 1 study testing ONO-7913, ONO-4538 and Oxaliplatin in people with Metastatic Pancreatic Cancer, run by Ono Pharmaceutical Co., Ltd. at 9 sites in Japan.
Trial summary
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Metastatic Pancreatic Cancer
- What is being tested?
- ONO-7913, ONO-4538 and Oxaliplatin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 9 sitesJapan
- Study dates
- 30 Jul 2021to 30 Jun 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Untreated metastatic pancreatic cancer
- 2. Life expectancy of at least 3 months
- 3. Patients with ECOG performance status 0 or 1
Who cannot join
- 1. Patients with severe complication
- 2. Patients with multiple primary cancers
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
Japan9 sites
Juntendo University Hospital
Bunkyō-Ku, Tokyo
The University of Tokyo Hospital
Bunkyō-Ku, Tokyo
National Cancer Center Hospital
Chūōku
Seirei Hamamatsu General Hospital
Hamamatsu, Shizuoka
National Cancer Center Hospital East
Kashiwa-shi, Chiba
The Cancer Institute Hospital ofJFCR
Koto-ku, Tokyo
Kyorin University Hospital
Mitaka-shi, Tokyo
Keio University Hospital
Shinjuku-Ku, Tokyo
Kanagawa Cancer Center
Yokohama, Kanagawa
About this study
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
- Conditions
- Metastatic Pancreatic Cancer
- Being tested
- ONO-7913, ONO-4538, Oxaliplatin, Levofolinate, Irinotecan
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ONO-7913Drug
Also called Magrolimab
Specified dose on specified days
ONO-4538Drug
Also called Nivolumab
Specified dose on specified days
OxaliplatinDrug
Specified dose on specified days
LevofolinateDrug
Specified dose on specified days
IrinotecanDrug
Specified dose on specified days
FluorouracilDrug
Specified dose on specified days
| Study group | Role | What they receive |
|---|---|---|
| ONO-7913+ONO-4538+mFFX | Experimental | Not described Receives: Drug: ONO-7913; Drug: ONO-4538; Drug: Oxaliplatin; Drug: Levofolinate; Drug: Irinotecan; Drug: Fluorouracil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose-limiting toxicities（DLT）
Measured: 28 days
Adverse event(AE)
Measured: UP to 30 days after the last dose
Secondary outcomes (12)
Pharmacokinetics（serum concentration of ONO-7913）
Measured: Through study completion, an average of 6 months
Pharmacokinetics（serum concentration of ONO-4538）
Measured: Through study completion, an average of 6 months
Overall response rate (ORR)
Measured: Through study completion, an average of 6 months
Disease control rate (DCR)
Measured: Through study completion, an average of 6 months
Overall survival (OS)
Measured: Through study completion, an average of 6 months
Progression-free survival (PFS)
Measured: Through study completion, an average of 6 months
Duration of response (DOR)
Measured: Through study completion, an average of 6 months
Time to response (TTR)
Measured: Through study completion, an average of 6 months
Best overall response (BOR)
Measured: Through study completion, an average of 6 months
Percentage of change in the sum of tumor diameters of target lesions
Measured: Through study completion, an average of 6 months
Maximum percentage of change in the sum of tumor diameters of target lesions
Measured: Through study completion, an average of 6 months
Changes in tumor markers (CEA and CA19-9)
Measured: Through study completion, an average of 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2024
- Study start30 Jul 2021
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metastatic Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by Ono Pharmaceutical Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Project Leader, Study director, Ono Pharmaceutical Co., Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06532344
- Sponsor's protocol ID
- ONO-7913-03
- Other IDs
- jRCT2031210172
- Status last verified
- Oct 2026
- First submitted
- 29 Jul 2024
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- ClinicalTrials.gov ID
- NCT06532344
- Acronym / sponsor ID
- ONO-7913-03
- Conditions
- Metastatic Pancreatic Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 30 Jul 2021 (actual)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 1 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ONO-7913+ONO-4538+mFFX | Experimental | Drug: ONO-7913, Drug: ONO-4538, Drug: Oxaliplatin, Drug: Levofolinate, Drug: Irinotecan, Drug: Fluorouracil |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- 1. Untreated metastatic pancreatic cancer
- 2. Life expectancy of at least 3 months
- 3. Patients with ECOG performance status 0 or 1
Key exclusion criteria (2 listed)
- 1. Patients with severe complication
- 2. Patients with multiple primary cancers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ONO-7913Also: MagrolimabSpecified dose on specified days | Drug | ONO-7913+ONO-4538+mFFX |
| ONO-4538Also: NivolumabSpecified dose on specified days | Drug | ONO-7913+ONO-4538+mFFX |
| OxaliplatinSpecified dose on specified days | Drug | ONO-7913+ONO-4538+mFFX |
| LevofolinateSpecified dose on specified days | Drug | ONO-7913+ONO-4538+mFFX |
| IrinotecanSpecified dose on specified days | Drug | ONO-7913+ONO-4538+mFFX |
| FluorouracilSpecified dose on specified days | Drug | ONO-7913+ONO-4538+mFFX |
Primary outcome
Dose-limiting toxicities（DLT）
Time frame: 28 days
Adverse event(AE)
Time frame: UP to 30 days after the last dose
12 secondary outcomes
Pharmacokinetics（serum concentration of ONO-7913）
Time frame: Through study completion, an average of 6 months
Pharmacokinetics（serum concentration of ONO-4538）
Time frame: Through study completion, an average of 6 months
Overall response rate (ORR)
Time frame: Through study completion, an average of 6 months
Disease control rate (DCR)
Time frame: Through study completion, an average of 6 months
Overall survival (OS)
Time frame: Through study completion, an average of 6 months
Progression-free survival (PFS)
Time frame: Through study completion, an average of 6 months
Duration of response (DOR)
Time frame: Through study completion, an average of 6 months
Time to response (TTR)
Time frame: Through study completion, an average of 6 months
Best overall response (BOR)
Time frame: Through study completion, an average of 6 months
Percentage of change in the sum of tumor diameters of target lesions
Time frame: Through study completion, an average of 6 months
Maximum percentage of change in the sum of tumor diameters of target lesions
Time frame: Through study completion, an average of 6 months
Changes in tumor markers (CEA and CA19-9)
Time frame: Through study completion, an average of 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Metastatic Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer, Pancreatic Cancer Metastatic
Recruiting
CREO - Microwave Ablation Feasibility Study
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Project Leader study director
Ono Pharmaceutical Co., Ltd.
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ONO-7913, ONO-4538 and Oxaliplatin in people with Metastatic Pancreatic Cancer, run by Ono Pharmaceutical Co., Ltd. at 9 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dose-limiting toxicities（DLT） (time frame: 28 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026; AzTrials last refreshed its copy on 6 Nov 2026.